Challenges and Impact of Formulation on Exposure to Drive PKPD in CNS Drug Discovery

13:35 - 14:10

  • Early discovery compound characteristics often make high exposure for PKPD necessary and difficult to achieve
  • Driving CNS exposure is even more challenging due to the blood brain barrier
  • Dosing strategies to address this challenge are complicated and yield mixed results

Doug Burdette, Director, DMPK, Biogen